You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response

Article metrics

Article menu

Download PDFPDF

XML
Case Report
Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response

 

Online download statistics by month:

Online download statistics by month: January 2020 to March 2026

AbstractFullPdf
Jan 2020880
Feb 202041410
Mar 202034343
Apr 2020202022
May 2020646415
Jun 2020252524
Jul 2020303015
Aug 2020191955
Sep 2020343422
Oct 2020212123
Nov 2020242313
Dec 202020206
Jan 2021343413
Feb 202127277
Mar 2021303015
Apr 2021292914
May 202114146
Jun 2021222215
Jul 2021171712
Aug 202112128
Sep 2021181815
Oct 2021232332
Nov 2021282831
Dec 2021262825
Jan 2022242528
Feb 2022141416
Mar 2022181810
Apr 2022242611
May 2022182015
Jun 2022242518
Jul 2022161715
Aug 2022181815
Sep 2022212417
Oct 2022212110
Nov 2022323216
Dec 202225252
Jan 2023191912
Feb 202312132
Mar 2023191911
Apr 2023151614
May 20239910
Jun 2023550
Jul 2023999
Aug 2023202011
Sep 2023996
Oct 2023776
Nov 202320207
Dec 202317174
Jan 202414147
Feb 2024252515
Mar 2024252511
Apr 2024192010
May 2024212211
Jun 2024282714
Jul 2024404015
Aug 202419198
Sep 2024191911
Oct 2024202011
Nov 202415168
Dec 2024111111
Jan 2025222214
Feb 2025313114
Mar 2025292921
Apr 202549498
May 2025434318
Jun 202530309
Jul 2025110
Sep 2025100
Mar 2026110
Total14991513872